DR. ALEXANDER RICHARD STALLER D.O.
Prescription History 1497101919
Internal Medicine - Pulmonary Disease in Omaha, NE

NPI Status: Active since May 13, 2016

Contact Information

7710 MERCY RD STE 3000
OMAHA, NE
ZIP 68124
Phone: (402) 717-9600
Fax: (402) 717-6014

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ALEXANDER RICHARD STALLER D.O., an active Pulmonary Disease specialist practicing in Omaha, NE. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 62 documented patient claims. Among these therapy options, the most frequently utilized medication is Adempas, which accounts for 19 claims alone.

Medication Index

No matching medications currently found on file.

Adempas

Generic Formulation: RiociguatSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
NE State Average Benchmarks
Peer Average Claims94.0
Peer Average 30-Day Fills94.2
Peer Average Days Supply2,775
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.8% less volume than the regional standard for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $260,105.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,689.74

State Avg Cost Per Claim

$12,684.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Riociguat is used to treat high blood pressure in the lungs (pulmonary hypertension). It can also be used to treat a certain type of high blood pressure in the lungs caused by blood clots (chronic thromboembolic pulmonary hypertension) when surgery has not been fully successful or is impossible. Riociguat works by relaxing and widening the blood vessels in your lungs so blood can flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

Ambrisentan

Generic Formulation: AmbrisentanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NE State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills43.1
Peer Average Days Supply1,288
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.0% less volume than the regional standard for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $45,895.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,824.65

State Avg Cost Per Claim

$4,716.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ambrisentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, thereby helping to decrease the blood pressure in the lungs, slow the worsening of symptoms, and improve your ability to exercise.

Sildenafil Citrate

Generic Formulation: Sildenafil CitrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 20.0
Days Supply 600
NE State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills29.3
Peer Average Days Supply830
Conservative Utilization

This provider writes prescriptions for this formulation 27.3% less frequently than the standard regional baseline metric for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,501.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$281.32

State Avg Cost Per Claim

$141.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.

Therapeutic Applications

Sildenafil is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise. This medication is not recommended for use in children. Discuss the risks and benefits of this medication with the doctor.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 25.0
Days Supply 750
NE State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills53.0
Peer Average Days Supply1,584
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,901.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,126.79

State Avg Cost Per Claim

$769.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ALEXANDER RICHARD STALLER D.O. provides transparency into local medical care patterns within Omaha, NE.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.